MIRM · NASDAQ · STOCK
Mirum Pharmaceuticals (MIRM) Stock Analysis
$86.04
52W $63.23 – $130.00
50/100
$5.24B
-5.9
0.49
Is MIRM Bullish or Bearish?
Mixed.
Innellis AI committee rates Mirum Pharmaceuticals, Inc. (MIRM) Watch with a composite score of 50/100
, based on 6 analysts with 33% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +9.78 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -10.22 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Value Analyst remains cautious — price-to-book of 13.0x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 44.0% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Price-to-book of 13.0x prices in significant intangible value — Value
- ROE of only -289.3% -- cheap may mean cheap for a reason — Value
- 3 consecutive earnings misses -- execution concerns — Growth
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 26.1% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
50/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 93%
of 192 Healthcare peers
Value Analyst
bearish
30
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 13.0x prices in significant intangible value
Growth Analyst
bullish
63
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 44.0% YoY -- genuine top-line momentum
− 3 consecutive earnings misses -- execution concerns
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 26.1% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 48.6 to 50.2.
- Committee agreement fell notably from 50% to 33%.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
- Analyst(s) changed stance: Technical Analyst.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: stance bearish->neutral; score 38->48 (+10).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
51.7
Neutral
MACD Histogram
-0.133
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Lh Ll
Support
$85.22
Resistance
$109.00
Bollinger %B
0.40
Inside Bands
Price vs Moving Averages
EMA 9
$83.96
Above
EMA 21
$87.90
Below
EMA 50
$94.26
Below
EMA 200
$94.17
Below
Fundamental Analysis
Valuation
100
Growth
32
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-5.9×
P/B Ratio
—
PEG Ratio
0.00
Dividend Yield
0.00%
52W High
$130.00
52W Low
$63.23
Quality & Growth
ROE
-742.4%
ROA
-277.2%
Gross Margin
8170.1%
Operating Margin
-1741.9%
Revenue Growth YoY
—
Debt / Equity
—
AI Fundamental Assessment
P/E ratio of -5.9 (inexpensive relative to a 15-40x range); Price-to-book of -523.0x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -7.4%; Return on assets of -2.8%; Net margin of -139.2%; Gross margin of 81.7%; Current ratio of 2.86 (healthy short-term liquidity); Debt-to-equity of -72.97; Free cash flow per share is negative (-7.23); Most recent quarter missed estimates by 52.6%; 3 consecutive earnings misses; EPS growth accelerating (-980.0% -> +1.9% QoQ); Analyst estimates falling over recent quarters
Get the Full MIRM Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →